Nausea and vomiting are very common in early pregnancy, and the victims have to ingest multiple medications. About 5% of them are known to consume some form of cannabinoid. The bad news is that little is known about its effectiveness to both the mother and the developing fetuses. However, the good news is that Tauriga Sciences, Inc. (OTCMKTS: TAUG) has commenced a clinical trial to ascertain the effects of Cannabidiol on pregnant women.
Women with Hyperemesis Gravidarum diagnosis will form the primary subjects of the trial. They must also have Excessive First Trimester Emesis. Unlike alcohol, there is no known congenital disability identified to have been caused by CBD or THC. Additionally, pregnant women are hardly subjects of clinical trials presenting demanding scientific data despite being a vulnerable population.
Nonetheless, Dr. Keith Aqua Tauriga’s Chief Medical Officer explained, “…We intend to add to the fund of knowledge regarding the effects of CBD on pregnant women by performing this and other scientific clinical trials.”
The Launch of Tauriga’s Pharmaceutical Development Initiative
The New York-based diversified Life Sciences Company boasts several business activities, initiatives, and activities, including manufacturing and distributing proprietary retail products and product lines. A proprietary supplement chewing gum branded as Tauri-Gum is the main product line.
All these retail businesses compliment Tauriga’s ongoing Pharmaceutical Development initiatives. This makes it the only company evaluating Cannabidiol concerning pregnant women. And if all right, the industry may result in the making pharmaceutical-grade version of Tauri-Gum for nausea regulation.
Tauriga Sciences, Inc.Renews its US Federal Government Vendor Status
The company successfully obtained a US Federal Government Vendor status in early October 2020. This status has expanded to extraordinary heights, enhancing its diversification of products and product lines. And having identified multiple potential government contract opportunities, the company has renewed its status.
Tauriga works directly with FAMR, an independent consulting firm specializing in identifying future opportunities before Registration, Certification, and Federal Contracting.
Tauriga Sciences, Inc. (OTCMKTS: TAUG) Sets up a Clinical Trial to Determine the effects of Cannabidiol on Pregnant Women with a Hyperemesis Gravidarum Diagnosis.
Post Views: 2 Nausea and vomiting are very common in early pregnancy, and the victims have to ingest multiple medications....
BetterLife Pharma Inc. (OTCMKTS: BETRF) Announce Initiation Of In Vitro Studies of AP-003 Against The Delta Variant of SARS-CoV-2
Post Views: 2 Depression impacts approximately 265 million people in the world. According to WHO, it is one of the...
Ayr Wellness Inc. (OTCMKTS: AYRWF) Signs a Binding Letter of Intent to Acquire PA Natural Medicine, LLC
Post Views: 6 Curiosity about cannabis is building by the day as more expert cultivators, manufactures, budtenders, and patient consultants...
Schwazze (OTCMKTS: SHWZ) Spends $6.7 Million to Acquire the Assets of Brow 2, LLC, Located in Denver, Colorado
Post Views: 14 Innovative thinking is what will keep the next era of the cannabis industry alive. This is according...
Valens Company Inc (OTCMKTS: VLNCF) Acquires Leading, Premium Craft Licensed producer, Citizen Stash Cannabis Corp
Post Views: 87 Valens Company Inc (OTCMKTS: VLNCF), a leading manufacturer of cannabis products, announced that it entered into an...
Harvest One Cannabis Inc’s (OTCMKTS: HRVOF) Dream Water Brand Launches its Sleep Gummies into the American Market
Post Views: 92 Harvest One Cannabis Inc (OTCMKTS: HRVOF) reported that its Dream Water launched sleep gummies for a new...